Top Industry Leaders in the Bone Cancer Market
BeiGene receives US FDA Breakthrough Therapy Designation for tislelizumab (an anti-PD-1 monoclonal antibody) for the treatment of locally advanced unresectable or metastatic osteosarcoma, potentially accelerating its pathway to market.
AstraZeneca's IMblaze 410 trial investigating Imfinzi (durvalumab) in combination with chemotherapy met its primary endpoint, showing improved overall survival in patients with stage III resectable osteosarcoma after surgery.
Seagen secures Fast Track designation from the US FDA for tucatinib (a HER2 tyrosine kinase inhibitor) in combination with other standard therapies for advanced bone cancer with HER2 alterations.
Eli Lilly and Innovent Biologics form a strategic partnership to develop and commercialize innovative therapies for bone cancer and other cancers. This collaboration combines their expertise and resources to accelerate drug development and market access.
Bristol-Myers Squibb and Checkmate Pharmaceuticals agree to co-develop and commercialize OPB-838, a novel drug candidate with potential for bone cancer treatment, leveraging their combined strengths in clinical development and commercialization.
List of Bone Cancer Key Companies in the Market
- Shanghai Henlius Biotech
- Zydus Pharmaceuticals
- Roxane Laboratories
- Baxter International Inc.
- Boehringer Ingelheim
- West-Ward Pharmaceuticals
- Perrigo Company
- Mylan Pharmaceuticals
- Fresenius Kabi USA LLC
- Amgen, Novartis Pharmaceuticals
- Amneal Pharmaceuticals
- Teva Pharmaceuticals
- Sandoz Inc.
- Jubilant Cadista Pharmaceuticals
